Status:
RECRUITING
BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
Schweizerische Multiple Sklerose Gesellschaft
University of Bern
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to investigate new quantitative MRI-sequences for assessment of age-specific data for the prediction of brain aging.
Detailed Description
After being informed about the study, healthy controls and patients with multiple sclerosis giving written informed consent will undergo blood examination (for determination of the biological age usin...
Eligibility Criteria
Inclusion
- Informed Consent signed by the subject
- Group 1: Any healthy individual between 18 and 65 years of age
- Group 2: Any individuals with any diagnosis of Multiple Sclerosis between 18 and 65 years of age and EDSS ≤6.0.
Exclusion
- Group 1 and 2: Any other neurological disease except primary headaches: insufficient language skills in German or French; pregnancy, lactation, any contraindication for MRI (active implants, passive ferromagnetic implants, passive non-ferromagnetic metallic implants \>4cm in the region covered by the active RF coils, large tattoos inside a region covered by the active radiofrequency (RF) coils, claustrophobia or suspected/known non-compliance), smoking within the last 10 years prior recruitment, any other drug consumption except moderate alcohol intake (less than a standard drink containing 10 grams of alcohol per day) or use of medical cannabis, any previous head trauma (with known/suspected intracranial consequences), Body Mass Index (BMI) \>30, and any other chronic progressive disease.
- Specific Criteria for group 1: The calculated biological age (BioAge R Package algorithm) differs by \> +/- 3 years from the chronological age. These patients will not be further invited for a study visit with clinical examination and MRI.
- Specific Criteria for group 2: EDSS \> 6.0 as this impacts physical testing; clinical relapse within the last 6 months
Key Trial Info
Start Date :
August 27 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06221631
Start Date
August 27 2024
End Date
March 1 2028
Last Update
November 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital Bern
Bern, Switzerland, 3010